ApoPharma’s START Study Now Recruiting Participants
September 20, 2018 – The START study is examining the effects of giving early treatment of deferiprone to young children with beta thalassemia who have started receiving regular blood transfusions but have not yet reached the criteria for starting on iron chelation therapy. There are 2 trial sites in the US: Los Angeles and Philadelphia.
Learn more about this study at: https://clinicaltrials.gov/ct2/show/NCT03591575
CAF periodically provides information on studies that may be of interest to members of the thalassemia community. Our sharing of information does not constitute an endorsement of any one trial or study.